PROMISING APPROACHES IN PREDICTING THE COURSE OF BREAST CANCER IN OVERWEIGHT (review of literature data and our own research)
DOI:
https://doi.org/10.15407/oncology.2025.02.103Keywords:
breast cancer, obesity, neutrophil to lymphocyte ratio, platelet gelatinaseAbstract
Summary. The authors reviewed, analyzed and summarized the data of modern scientific literature and the results of their own research on promising approaches to the prognosis of breast cancer (BC) in overweight women. In particular, the article discusses the role of blood biomarkers, namely the ratio of neutrophils to lymphocytes, platelets and their gelatinases, in predicting the course of breast cancer in obesity. Breast cancer is one of the most common malignant tumours in women, and its development is caused by both genetic and modified risk factors, with special attention paid to hormonal and reproductive aspects in overweight patients. Obesity is considered as one of the factors that worsens the results of breast cancer treatment, especially in postmenopausal women. It is noted that an excess of adipose tissue contributes to the development of a pro-inflammatory state that affects the aggressiveness of the tumour. Special attention is also paid to the role of systemic inflammation, which is characterized, in particular, by the ratio of neutrophils to lymphocytes, high levels of which are associated with poor survival rates in breast cancer patients, especially in postmenopausal women. The role of platelets in predicting the course of the tumour is also discussed, in particular through the regulation of angiogenesis and metastasis.
References
Obeagu EI, Babar Q, Vincent CC, et al. Therapeutic tar- gets in breast cancer signaling: a review. J Pharm Res Int 2021; 33: 82–99. https://doi.org/10.9734/JPRI/2021/v33 i56A33889
Aizaz M, Khan M, Khan FI, et al. Burden of breast cancer: developing countries perspective. Int J Innov Appl Res 2023; 11: 31–7. https://doi.org/10.58538/IJ
Ibekwe AM, Obeagu EI, Ibekwe CE, et al. Challenges of exclusive breastfeeding among working class women in a teaching hospital South East, Nigeria. J Pharm Res Int 2022; 34 (46A): 1–10. https://doi.org/10.9734/jpri/2022/ v34i46A36371
Sun YS, Zhao Z, Yang ZN, et al. Risk factors and preventions of breast cancer. Int J Biol Sci 2017; 13: 1387–97. https:// doi.org/10.7150/ij s.21635
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317 (23): 2402– 12. https://doi.org/10.1001/jama.2017.7112
Britt K. Menarche, menopause, and breast cancer risk. Lan- cet Oncol 2012; 13 (11): 1071–2. https://doi.org/10.1016/ S1470-2045(12)70425-4
Sanchez-Covarrubias AP, Chery MJ, Barreto-Coehlo P, et al. Reproductive risk factor patterns in Caribbean wom- en with breast cancer across 4 generations. JAMA Netw Open 2024; 7 (10): e2438091. https://doi.org/10.1001/ jamanetworkopen.2024.38091
Obeagu EI, Obeagu GU. Breast cancer: a review of risk fac- tors and diagnosis. Medicine 2024; 103 (3): e36905. https:// doi.org/10.1097/MD.0000000000036905.
Lei S, Zheng R, Zhang S, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond) 2021; 41 (11): 1183–94. https://doi.org/10.1002/ cac2.12207
Park WK, Nam SJ, Kim SW, et al. The prognostic impact of HER2-low and menopausal status in triple-negative breast cancer. Cancers 2024; 16 (14): 2566. https://doi.org/ 10.3390/cancers15225361
Kim J, Harper A, McCormack V, et al. Global patterns and trends in breast cancer incidence and mortality across 185 countries. Nat Med 2025; 31 (4): 1154–62. https://doi. org/10.1038/s41591-025-03502-3
International Agency for Research on Cancer, World Health Organization. Estimated numbers of new cases and death from breast cancer from 2022 to 2050, Females, age [0–85+]. Available at: https://gco.iarc.who.int/tomorrow/ en/dataviz/trends?multiple_populations=1&cancers= 20&populations=903_904_905_908_909_935&group_ populations=1&types=0_1&sexes=2
World Atlas of Obesity 2024; World Obesity Federation: London, UK, 2024. Available at: https://www.worldobesity. org/resources/resource-library/world-obesity-atlas-2024
Janez A, Muzurovic E, Bogdanski P, et al. Modern manage- ment of cardiometabolic continuum: from overweight/ obesity to prediabetes/type 2 diabetes mellitus. Recommen- dations from the Eastern and Southern Europe Diabetes and Obesity Expert Group. Diabetes Ther 2024; 15: 1865–92. https://doi.org/10.1007/s13300-024-01615-5
Janić M, Janež A, El-Tanani M, Rizzo M. Obesity: recent advances and future perspectives. Biomedicines 2025; 13 (2): 368. https://doi.org/10.3390/biomedicines1302 0368
World Health Organization. Obesity. 2024. Available at: https://www.who.int/health-topics/obesity#tab=tab_1
García-Estévez L, González-Rodríguez M, Calvo I, et al. Obesity, overweight and breast cancer: new clinical data and implications for practice. Front Oncol 2025; 15: 1579876. https://doi.org/10.3389/fonc.2025.1579876
Garcia-Estevez L, Cortes J, Perez S, et al. Obesity and breast cancer: a paradoxical and controversial relationship influen- ced by menopausal status. Front Oncol 2021; 11: 705911. https://doi.org/10.3389/fonc.2021.705911
Engin A. Obesity-associated breast cancer: analysis of risk factors and current clinical evaluation. Adv Exp Med Biol 2024; 1460: 767–819. https://doi.org/10.1007/978-3-031- 63657-8_26
World Obesity Federation. World Obesity Atlas. 2023. Avail- able at: https://www.worldobesity.org/resources/resource- library/world-obesity-atlas-2023
Dehesh T, Fadaghi S, Seyedi M, et al. The relation between obesity and breast cancer risk in women by considering menstruation status and geographical variations: a system- atic review and meta-analysis. BMC Womens Health 2023; 23 (1): 392. https://doi.org/10.1186/s12905-023-02543-5
Ifeanyi E, Uzoma G. Breast cancer: a review of risk factors and diagnosis. Medicine 2024; 103 (3): e36905. https:// doi.org/10.1097/MD.0000000000036905
Schon SB, Cabre HE, Redman LM. The impact of obesity on reproductive health and metabolism in reproductive-age females. Fertil Steril 2024; 122 (2): 194–203. https://doi.
org/10.1016/j.fertnstert.2024.04.036
Tiainen S, Rilla K, Hämäläinen K, et al. The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype. Breast Cancer Res Treat 2021; 185: 63–72. https://doi.org/10.1007/s10549-020- 05925-7
Heshmat-Ghahdarij K, Sarmadi V, Heidari A, et al. The neutrophil-to-lymphocyte ratio as a new prognostic fac- tor in cancers: a narrative review. Front Oncol 2023; 13: 1228076. https://doi.org/10.3389/fonc.2023.1228076
Zahorec R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives. Bratisl Lek Listy 2021; 122 (7): 474–88. https://doi.org/10.4149/BLL_2021_078
Buonacera A, Stancanelli B, Colaci M, Malatino L. Neu- trophil to lymphocyte ratio: an emerging marker of the relationships between the immune system and diseases. Int J Mol Sci 2022; 23 (7): 3636. https://doi.org/10.3390/ ij 3073636
Zhou Q, Dong J, Sun Q, et al. Role of neutrophil-to-lympho- cyte ratio as a prognostic biomarker in patients with breast cancer receiving neoadjuvant chemotherapy: a meta-analy- sis. BMJ Open 2021; 11: e047957. https://doi.org/10.1136/ bmjopen-2020-047957
Ding N, Huang J, Li N, et al. Roles of neutrophil/lympho- cyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastu- zumab therapy. BMC Cancer 2020; 20: 235. https://doi. org/10.1186/s12885-020-06750-3
Bae SJ, Cha YJ, Yoon C, et al. Prognostic value of neutro- phil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neo- adjuvant chemotherapy. Sci Rep 2020; 10: 13078. https:// doi.org/10.1038/s41598-020-69965-1
Ijichi H, Tajiri W, Koi Y, et al. Preoperative neutrophil-to- lymphocyte ratio in postmenopausal breast cancer patients. J Surg Res 2024; 296: 98–105. https://doi.org/10.1016/j. jss.2023.11.075
Bubnovskaya LM, Samoylenko OA, Verbinenko AV, Ganu- sevich II. Tumor-associated adipocytes in the prognostic application of the preoperative ratio of neutrophils and lymphocytes in breast cancer. Problems and Achievements of Modern Biotechnology. Kharkiv, 2024: 170–1. https:// biotech.nuph.edu.ua/wp-content/uploads/2024/04/tezy_ iv_mizhnarodnoi_naukovo_praktychnoi_internet_konfer- entsii_problemy.pdf
Obeagu EI. Platelet activation in breast cancer: mechanisms and therapeutic opportunities — a narrative review. Ann Med Surg 2025; 87 (6): 3356–61. https://doi.org/10.1097/ MS9.0000000000003091
Anwar SL, Cahyono R, Avanti WS, et al. Pre-treatment neutrophil-lymphocyte and platelet-lymphocyte ratios as additional markers for breast cancer progression: a retro- spective cohort study. Ann Med Surg 2021; 63: 102144. https://doi.org/10.1016/j.amsu.2021.01.092
Hurmuz P, Ozyigit G, Kilickap S, et al. Gemcitabine based trimodality treatment in patients with muscle invasive blad- der cancer: may neutrophil lymphocyte and platelet lym- phocyte ratios predict outcomes? Urol Oncol 2021; 39 (6): 368.e19–e29. https://doi.org/10.1016/j.urolonc.2020.11. 006
Wang Y, Tang Y, Gao X, et al. Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and Ga-PSMA-PET-derived SUVmax values. Prostate 2022; 82 (15): 1415–21. https://doi.org/10.1002/pros. 24415
Wang L, Zhang K, Feng J, et al. The progress of platelets in breast cancer. Cancer Manag Res 2023; 15: 811–21. https:// doi.org/10.2147/CMAR.S418574
D’Ambrosi S, Nilsson RJ, Wurdinger T. Platelets and tumor- associated RNA transfer. Blood 2021; 137 (23): 3181–91. https://doi.org/10.1182/blood.2019003978
Miao S, Zhang Q, Chang W, Wang J. New insights into platelet-enriched miRNAs: production, functions, roles in tumors, and potential targets for tumor diagnosis and treatment. Mol Cancer Ther 2021; 20 (8): 1359–66. https:// doi.org/10.1158/1535-7163.MCT-21-0050
Best MG, Sol N, Vancura A, et al. Swarm intelligence- enhanced detection of non-small-cell lung cancer using tumor-educated platelets. Cancer Cell 2017; 32 (2): 238–52. e9. https://doi.org/10.1016/j.ccell.2017.07.004
Karolczak K, Watala C. Blood platelets as an important but underrated circulating source of TGFβ. Int J Mol Sci 2021; 22 (9): 4492. https://doi.org/10.3390/ij 94492
Karsten MM, Beck MH, Rademacher A, et al. VEGF-A165b levels are reduced in breast cancer patients at primary di- agnosis but increase after completion of cancer treatment. Sci Rep 2020; 10 (1): 3635. https://doi.org/10.1038/s41598- 020-59823-5
Ward MP, Kane LE, Norris LA, et al. Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell? Mol Cancer 2021; 20 (1): 59. https://doi.org/ 10.1186/s12943-021-01347-1
Abdel-Hamid NM, Abass, et al. Matrix metalloproteinase contribution in management of cancer proliferation, metas- tasis and drug targeting. Mol Biol Rep 2021; 48: 6525–38. https://doi.org/10.1007/s11033-021-06635-z
Wu J, Heemskerk JW, Baaten CC. Platelet membrane recep- tor proteolysis: implications for platelet function. Front Cardiovasc Med 2021; 7: 608391.
Ganusevich II, Samoylenko OA, Verbinenko AV, Tropynina OS. Platelet gelatinases and survival of breast cancer patients with obesity: the relationship with menopausal status. Oncology 2024; 26 (2): 139–45. https://doi.org/10.15407/oncology. 2024.02.139 (in Ukrainian)
Ganusevich II, Virko SV, Riznichuk VO. Breast cancer in obesity: menopausal status and redox characteristics of adipose tissue dysfunction. Oncology 2023; 25 (2): 115–21. https://doi.org/10.15407/oncology.2023.02.115 (in Ukrai- nian)
Tropynina OS, Ganusevich II. Platelet gelatinase activ- ity in the course of breast cancer in obesity: dependence on menopausal status. From experimental and clinical pathophysiology to the achievements of modern medi- cine and pharmacy. Kharkiv, 2024: 209–10. https://pat. nuph.edu.ua/wp-content/uploads/2024/05/zbirnyk-konf- 16.05.24-1.pdf (in Ukrainian)
Ganusevich II, Samoylenko OA, Verbinenko AV, Tropyni- na OS. Redox state of blood and menopausal status of breast cancer patients with obesity. Abstracts of the Con- ference “Assessment of Quality of Life in Cancer Patients Covered in Experimental and Clinical Oncology Publica- tions: Challenges and Opportunities”, October 3–4, 2024, Kyiv, Ukraine. Exp Oncol 2024; 46 (4): 411. https://doi. org/10.15407/exp-oncology/2024.04.410
Abdul Rahman H, Zaim SNN, Suhaimei US, Jamain AA. Prognostic factors associated with breast cancer-specifi survival from 1995 to 2022: a systematic review and meta- analysis of 1,386,663 cases from 30 countries. Diseases 2024; 12 (6): 111. https://doi.org/10.3390/diseases12060111
Zhou Y, Yu S, Zhu L, et al. Molecular biomarkers for the prognosis of breast cancer: role of amino acid metabolism genes. J Physiol Biochem 2025. https://doi.org/10.1007/ s13105-025-01088-5
Gao W, Yao Y, Gao Q, et al. Impact of serum lipids on prog- nosis in breast cancer patients: a systematic review and meta-analysis. World J Surg Onc 2025; 23: 234. https:// doi.org/ 10.1186/s12957-025-03875-2
